It Kills That: Cramer Won’t Recommend Pfizer 7% Yield
Jim Cramer declines to back Pfizer despite its 7% dividend, arguing the growth case isn’t clear. Pfizer sits near a 5...
Get a concise action plan for financial emergencies, including prioritizing essentials, securing funds, and communicating with creditors promptly.
16,835 articlesJim Cramer declines to back Pfizer despite its 7% dividend, arguing the growth case isn’t clear. Pfizer sits near a 5...
Ionis Pharmaceuticals dropped again after a Phase 3 failure in transthyretin amyloid cardiomyopathy, triggering a bro...
EU officials press for legal age gates and supervised use on europe social media platforms as part of a broader push ...
Stocks hover near record highs as earnings show resilience, but analysts warn that the gap between prices and profits...
OpenAI is stepping up its defense against prompt injection with a new AI red team. This shift could reshape how crypt...
California lawmakers return from summer break to push condo safety reforms, focusing on a true right-to-repair proces...
ServiceNow stock slipped today amid broader software fears and AI budget debates. Explore the drivers, what it means ...
Founders Fund has fully exited ETHZilla, and Peter Thiel has followed with a complete stake unload, underscoring a br...
MBA researchers project 2025 real GDP around 2.5% with consumer spending staying resilient, while FHA delinquencies r...
Bitcoin faces renewed downside pressure amid macro jitters, with traders watching key levels. Ripple's XRP eyes new t...
Bitcoin trades in a tight range after a sharp pullback, with big holders keeping their powder dry while retail buyers...
OpenAI's Sam Altman defended AI energy use at a major industry summit, arguing the footprint must be viewed against h...